Education

Graduate School

Washington University of St. Louis
St. Louis MO

Medical School

Washington University of St. Louis
St. Louis MO

Internship

Boston Children's Hospital
Boston MA

Residency

Boston Children's Hospital
Boston MA

Fellowship

Boston Children's Hospital
Boston MA

Publications

  1. Tear-Based Biomarker Trajectories Associated With Uveitis in Juvenile Idiopathic Arthritis: A Multicenter Prospective Study. Arthritis Care Res (Hoboken). 2026 Oct 20. View Abstract
  2. Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2025 08; 77(8):1092-1105. View Abstract
  3. Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Pediatr Rheumatol Online J. 2024 Oct 07; 22(1):88. View Abstract
  4. Kawasaki disease: contemporary perspectives. Lancet Child Adolesc Health. 2024 Oct; 8(10):781-792. View Abstract
  5. Measuring synovial thickness on knee MRI in pediatric patients with arthritis: is contrast necessary? Pediatr Radiol. 2024 05; 54(6):988-1000. View Abstract
  6. Elevation of IL-17 Cytokines Distinguishes Kawasaki Disease From Other Pediatric Inflammatory Disorders. Arthritis Rheumatol. 2024 02; 76(2):285-292. View Abstract
  7. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. J Clin Invest. 2023 11 15; 133(22). View Abstract
  8. In cis "benign" SOCS1 variants linked to enhanced interferon signaling and autoimmunity. J Autoimmun. 2023 11; 140:103119. View Abstract
  9. Development of a Screening Algorithm for Lung Disease in Systemic Juvenile Idiopathic Arthritis. ACR Open Rheumatol. 2023 Oct; 5(10):556-562. View Abstract
  10. Incidence and Risk Factors for Eosinophilia and Lung Disease in Biologic-Exposed Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2023 10; 75(10):2063-2072. View Abstract
  11. Disordered T cell-B cell interactions in autoantibody-positive inflammatory arthritis. Front Immunol. 2022; 13:1068399. View Abstract
  12. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023 03; 75(3):449-464. View Abstract
  13. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2023 03; 75(3):333-348. View Abstract
  14. An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome. J Rheumatol. 2022 Sep; 49(9):1042-1051. View Abstract
  15. Genetic diagnosis of immune dysregulation can lead to targeted therapy for interstitial lung disease: A case series and single center approach. Pediatr Pulmonol. 2022 07; 57(7):1577-1587. View Abstract
  16. Concepts in lupus pathophysiology: Lessons learned from disease across the spectrum. Clin Immunol. 2022 05; 238:109021. View Abstract
  17. New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases. Rheumatology (Oxford). 2022 04 11; 61(4):1610-1620. View Abstract
  18. Translating research into practice-implementation recommendations for pediatric rheumatology; Proceedings of the childhood arthritis and rheumatology research alliance 2020 implementation science retreat. Pediatr Rheumatol Online J. 2022 Feb 07; 20(1):10. View Abstract
  19. Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children. J Clin Rheumatol. 2022 Jan 01; 28(1):e301-e304. View Abstract
  20. Th1 polarization defines the synovial fluid T cell compartment in oligoarticular juvenile idiopathic arthritis. JCI Insight. 2021 09 22; 6(18). View Abstract
  21. Uveitis in Children and Adolescents. Rheum Dis Clin North Am. 2021 11; 47(4):619-641. View Abstract
  22. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J Allergy Clin Immunol. 2021 09; 148(3):732-738.e1. View Abstract
  23. Childhood Sjögren syndrome: features of an international cohort and application of the 2016 ACR/EULAR classification criteria. Rheumatology (Oxford). 2021 07 01; 60(7):3144-3155. View Abstract
  24. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol. 2021 08; 73(8):e46-e59. View Abstract
  25. Multiple Emergency Department Visits for a Diagnosis of Kawasaki Disease: An Examination of Risk Factors and Outcomes. J Pediatr. 2021 05; 232:127-132.e3. View Abstract
  26. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020 11 02; 130(11):5942-5950. View Abstract
  27. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol. 2020 11; 72(11):1809-1819. View Abstract
  28. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight. 2020 03 26; 5(6). View Abstract
  29. A framework for understanding Kawasaki disease pathogenesis. Clin Immunol. 2020 05; 214:108385. View Abstract
  30. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2020 02; 79(2):225-231. View Abstract
  31. Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population. J Am Heart Assoc. 2019 06 04; 8(11):e011319. View Abstract
  32. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Arthritis Care Res (Hoboken). 2019 04; 71(4):482-491. View Abstract
  33. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View Abstract
  34. Insights Gained From the Study of Pediatric Systemic Lupus Erythematosus. Front Immunol. 2018; 9:1278. View Abstract
  35. Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Curr Opin Rheumatol. 2018 03; 30(2):222-228. View Abstract
  36. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018 Jan; 21(1):64-69. View Abstract
  37. Adolescent and parent perspectives on medical decision-making for chronic illness. Fam Syst Health. 2018 06; 36(2):248-251. View Abstract
  38. Monogenic Hashimoto thyroiditis associated with a variant in the thyroglobulin (TG) gene. J Autoimmun. 2018 01; 86:116-119. View Abstract
  39. Predicting Coronary Artery Aneurysms in Kawasaki Disease at a North American Center: An Assessment of Baseline z Scores. J Am Heart Assoc. 2017 May 31; 6(6). View Abstract
  40. Monogenic Lupus. Curr Rheumatol Rep. 2016 Dec; 18(12):71. View Abstract
  41. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016 11 22; 12(12):716-730. View Abstract
  42. Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of Treg Cells in Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2016 07; 68(7):1758-68. View Abstract
  43. Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J. 2016 Feb 16; 14(1):9. View Abstract
  44. Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. J Allergy Clin Immunol. 2015 Jan; 135(1):272-3. View Abstract
  45. A70: medication use in the treatment of juvenile idiopathic uveitis patients enrolled in the childhood arthritis and rheumatology research alliance registry. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S102. View Abstract
  46. A119: deep sequencing analysis of the T regulatory and T effector repertoire in juvenile idiopathic arthritis. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S156. View Abstract
  47. A181: evaluating decision-making in a pediatric rheumatology clinic. Arthritis Rheumatol. 2014 Mar; 66 Suppl 11:S237. View Abstract
  48. Outcomes in hospitalized pediatric patients with systemic lupus erythematosus. Pediatrics. 2014 Jan; 133(1):e106-13. View Abstract
  49. Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study. Pediatr Rheumatol Online J. 2013 Nov 01; 11(1):42. View Abstract
  50. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013 Mar; 17(2):133-43. View Abstract
  51. cAMP response element modulator a controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A. 2012 Oct 09; 109(41):16606-11. View Abstract
  52. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci. 2012 Jan; 1247:138-52. View Abstract
  53. Methods and protocols to study T cell signaling abnormalities in human systemic lupus erythematosus. Methods Mol Biol. 2012; 900:25-60. View Abstract
  54. Sublingual desensitization for buprenorphine hypersensitivity. J Allergy Clin Immunol. 2010 Apr; 125(4):938-9. View Abstract
  55. Respiratory viral infections in immunocompromised children. Pediatric Academic Societies. 2009. View Abstract
  56. Anorexia Nervosa. Underground Clinical Vignettes: Pediatrics (edited by Kim S, Swanson T and Wasserman JD). 2007. View Abstract
  57. Varicella Zoster. Underground Clinical Vignettes: Pediatrics (edited by Kim S, Swanson T and Wasserman JD). 2007. View Abstract
  58. Improved IFN efficacy and viral clearance by engineering a Super-Stat1 transgene. American Thoracic Society. 2007. View Abstract
  59. Modification of the Stat1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment. J Biol Chem. 2005 Oct 07; 280(40):34306-15. View Abstract
  60. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol. 2005 Jul; 79(14):9315-9. View Abstract
  61. Defining and adjusting divergent host responses to viral infection. Immunol Res. 2005; 32(1-3):123-41. View Abstract
  62. Acute and chronic airway responses to viral infection: implications for asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2(2):132-40. View Abstract
  63. Immunity, inflammation, and remodeling in the airway epithelial barrier: epithelial-viral-allergic paradigm. Physiol Rev. 2002 Jan; 82(1):19-46. View Abstract
  64. Role of Stat1 in defense against respiratory viruses. Proceedings of Keystone Symposium: Molecular Aspects of Viral Immunity. 2001; 56. View Abstract
  65. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood. 1999 Nov 01; 94(9):3027-36. View Abstract

Contact Mindy Lo

Email: